PBI-Gordon Companies, Inc., the parent company of TriviumVet, which holds sole conditional new animal drug approval from the FDA for Felycin®-CA1 (sirolimus delayed-release tablets) under its affiliated brand company Pegasus, issued a cease-and-desist demand letter to Petspan for falsely promoting a compounded version of rapamycin (synonymous with sirolimus) for the treatment … [Read more...]